Allogene Therapeutics Q4 2023 GAAP EPS $(0.51) Misses $(0.46) Estimate, Sales $21.000K Miss $23.571K Estimate
Portfolio Pulse from Benzinga Newsdesk
Allogene Therapeutics reported Q4 2023 earnings with a GAAP EPS of $(0.51), missing the $(0.46) estimate, and sales of $21,000, missing the $23,571 estimate. This represents a 23.88% increase in EPS losses and a 19.23% decrease in sales from the same period last year.
March 14, 2024 | 8:17 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Allogene Therapeutics missed Q4 2023 earnings and sales estimates, with a larger loss per share and lower sales than expected.
Missing both earnings and sales estimates typically leads to negative investor sentiment in the short term, potentially causing a decrease in stock price. The reported increase in losses and decrease in sales from the previous year further contribute to a negative outlook.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100